Works matching IS 03407004 AND DT 2018 AND VI 67 AND IP 3
Results: 13
Acknowledgements.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 507, doi. 10.1007/s00262-018-2122-3
- Publication type:
- Article
High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 495, doi. 10.1007/s00262-017-2103-y
- By:
- Publication type:
- Article
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 341, doi. 10.1007/s00262-017-2099-3
- By:
- Publication type:
- Article
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 471, doi. 10.1007/s00262-017-2098-4
- By:
- Publication type:
- Article
Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 413, doi. 10.1007/s00262-017-2097-5
- By:
- Publication type:
- Article
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 445, doi. 10.1007/s00262-017-2095-7
- By:
- Publication type:
- Article
High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 403, doi. 10.1007/s00262-017-2093-9
- By:
- Publication type:
- Article
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 459, doi. 10.1007/s00262-017-2092-x
- By:
- Publication type:
- Article
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 381, doi. 10.1007/s00262-017-2091-y
- By:
- Publication type:
- Article
Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 423, doi. 10.1007/s00262-017-2090-z
- By:
- Publication type:
- Article
Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 393, doi. 10.1007/s00262-017-2089-5
- By:
- Publication type:
- Article
Prophylactic DNA vaccine targeting Foxp3<sup>+</sup> regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 367, doi. 10.1007/s00262-017-2088-6
- By:
- Publication type:
- Article
Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 353, doi. 10.1007/s00262-017-2087-7
- By:
- Publication type:
- Article